Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 1.00 |
| ▸ | RAB9A | P51151 | 5/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | GLA | P06280 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ELANE | P08246 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11119157 | 0.81 | RAB9A (0.68) | NPC1RAB9AHPGDSMN1; SMN2LMNA | |
| SCHEMBL2021003 | 0.75 | NPC1 (0.66) | NPC1RAB9AHPGDSMN1; SMN2LMNA | |
| SCHEMBL18344187 | 0.73 | NPC1 (0.57) | NPC1RAB9AHPGDSMN1; SMN2POLB | |
| SCHEMBL7126901 | 0.72 | NPC1 (0.55) | NPC1RAB9AHPGDSMN1; SMN2MBOAT4 | |
| SCHEMBL18344206 | 0.71 | NPC1 (0.55) | NPC1RAB9AHPGDSMN1; SMN2ELANE | |
| SCHEMBL2026325 | 0.71 | ALDH1A1 (1.00) | NPC1RAB9AHPGDSMN1; SMN2LMNA | |
| SCHEMBL28874364 | 0.71 | MBOAT4 (0.73) | NPC1RAB9AHPGDSMN1; SMN2LMNA | |
| SCHEMBL9184152 | 0.70 | RAB9A (0.54) | NPC1RAB9AHPGDSMN1; SMN2LMNA | |
| SCHEMBL1412324 | 0.70 | HPGD (0.73) | NPC1RAB9AHPGDSMN1; SMN2LMNA | |
| SCHEMBL2022339 | 0.70 | HPGD (0.71) | NPC1RAB9AHPGDSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150202195-A1 | SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2015-07-23 | — | — | US | claimed |
| US-9029376-B2 | Small molecule inhibitors for the treatment or prevention of dengue virus infection | SIGA TECHNOLOGIES, INC. (US) | 2015-05-12 | — | — | US | claimed |
| US-20110158940-A1 | SAMLL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2011-06-30 | — | — | US | claimed |
| EP-2293671-A1 | SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | Siga Technologies, Inc. (US) | 2011-03-16 | — | — | EP | claimed |
| WO-2009149054-A1 | SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2009-12-10 | — | — | WO | claimed |
| US-20150202195-A1 | SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2015-07-23 | — | — | US | disclosed |
| US-20150202195-A1 | SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2015-07-23 | — | — | US | disclosed |
| US-20150202195-A1 | SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2015-07-23 | — | — | US | disclosed |
| US-9029376-B2 | Small molecule inhibitors for the treatment or prevention of dengue virus infection | SIGA TECHNOLOGIES, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029376-B2 | Small molecule inhibitors for the treatment or prevention of dengue virus infection | SIGA TECHNOLOGIES, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029376-B2 | Small molecule inhibitors for the treatment or prevention of dengue virus infection | SIGA TECHNOLOGIES, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20110158940-A1 | SAMLL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110158940-A1 | SAMLL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110158940-A1 | SAMLL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2011-06-30 | — | — | US | disclosed |
| EP-2293671-A1 | SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | Siga Technologies, Inc. (US) | 2011-03-16 | — | — | EP | disclosed |
| WO-2009149054-A1 | SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009149054-A1 | SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202195-A1 | SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SNRPE, EIF2AK2, HAVCR2 | NPC1 696/4885RAB9A 966/4885HPGD 2186/4885 |
| US-20110158940-A1 | SAMLL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | HAVCR2, HNRNPLL, SAMSN1 | NPC1 1179/4885RAB9A 2107/4885HPGD 2847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.